


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound having a structure according to formula I



or ~~and~~ the pharmaceutically acceptable salts ~~salts, esters, and prodrug forms~~ thereof wherein

~~R¹ is OMe or R²R³N, where R² is H and R³ is~~ R¹ is H, allyl, or a substituted C₁-C₈ alkyl group substituted with a substituent selected from the group consisting of heteroaryl, aryl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, cycloalkoxy, heterocycloxy, alkanoyl, alkanoyloxy, amino, alkylamino, quaternary ammonium, aralkylamino, cycloalkylamino, heterocycloamino, dialkylamino, alkanoylamino, thio, alkylthio, cycloalkylthio, heterocyclothio, ureido, nitro, cyano, carboxy, carboxylalkyl, carbamyl, alkoxy carbonyl, alkylthiono, arylthiono, alkylsulfonyl, sulfonamido, and aryloxy, C₂-C₈ alkenyl, C₂-C₈ alkynyl, cycloalkyl, heterocyclo, aryl, or heteroaryl; or R² and R³ and the nitrogen to which they are attached combine to form an azetidinyl a-substituted or unsubstituted 3, 4, 5, 6, or 7 membered ring; and

~~R⁴ is H; or CH₂C(=O)R⁵, where R⁵ is a substituted or unsubstituted phenyl group.~~

wherein further

heteroaryl denotes a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic aryl ring system wherein each heteroaryl ring has 1, 2 or 3 heteroatoms

selected from N, O and S, where the N and S optionally may be oxidized and the N optionally may be quaternized;
cycloalkyl denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, or adamantyl; and
heterocyclo denotes a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system having at least one heteroatom in at least one carbon atom-containing ring, wherein each heterocyclic ring has 1, 2 or 3 heteroatoms selected from N, O and S, where the N and S optionally may be oxidized and the N optionally may be quaternized.

2-3. (Canceled)

4. (Currently Amended) A compound according to claim 1 [[2]], wherein ~~R¹ is R²R³N,~~ where R² is H and R³ is a substituted C₁-C₈ alkyl group.

5. (Original) A compound according to claim 4, wherein R³ is a substituted C₂ alkyl group.


6. (Original) A compound according to claim 5, wherein the substituent is selected from the group consisting of fluoro, cycloalkylamino, dialkylamino, heterocyclo having at least one nitrogen ring atom, and heteroaryl having at least one nitrogen ring atom.

7. (Currently Amended) A compound according to claim 1 [[2]], wherein ~~R¹ is R²R³N,~~ where R² is H and R³ is allyl.

8. (Original) A compound according to claim 1 [[2]], wherein ~~R¹ is R²R³N,~~ where R² and R³ are each is H.

9. (Currently Amended) A compound according to claim 1 [[2]], wherein ~~R¹ is R²R³N,~~ where R² and R³ and the nitrogen to which they are attached combine to form an azetidinyl a substituted or unsubstituted 3, 4, 5, 6, or 7 membered ring.

10. (Currently Amended) A compound according to claim 1 [[2]], wherein R¹ is selected from the group consisting of




11-16. (Canceled)


17. (Currently Amended) A method of inhibiting the proliferation of a target cell, comprising contacting a the target cell selected from the group consisting of a breast cancer, lung cancer, ovarian cancer, and leukemia cell with an effective amount of a compound having a structure according to claim 1.

18-19. (Canceled)


20. (Currently Amended) A method according to claim ~~17~~ 19, wherein the compound according to claim 1 has a structure according to formula I-b



21. (Currently Amended) A method according to claim ~~17~~ 19, wherein the compound according to claim 1 has a structure according to formula I-i




22. (Currently Amended) A method according to claim ~~17~~ 19, wherein the compound according to claim 1 has a structure according to formula I-j




23. (Currently Amended) A method of treating a hyperproliferative disease, comprising administering to a patient suffering from a ~~such~~ hyperproliferative disease selected from the group consisting of breast cancer, lung cancer, ovarian cancer, and leukemia a therapeutically effective amount of a compound according to claim 1.

24-25. (Canceled)


26. (Currently Amended) A method according to claim 23 ~~25~~, wherein the compound according to claim 1 has a structure according to formula I-b



27. (Currently Amended) A method according to claim 23 ~~25~~, wherein the compound according to claim 1 has a structure according to formula I-i



28. (Currently Amended) A method according to claim 23 ~~25~~, wherein the compound according to claim 1 has a structure according to formula I-j



29-34. (Canceled)